- Certain activating mutations within helix 6 of the human luteinizing hormone receptor may be explained by alterations that allow transmembrane regions to activate Gs. Abell, A.N., McCormick, D.J., Segaloff, D.L. Mol. Endocrinol. (1998)
- Identification of novel M phase phosphoproteins by expression cloning. Matsumoto-Taniura, N., Pirollet, F., Monroe, R., Gerace, L., Westendorf, J.M. Mol. Biol. Cell (1996)
- Designer drugs that are potent inhibitors of CYP2D6. Pritzker, D., Kanungo, A., Kilicarslan, T., Tyndale, R.F., Sellers, E.M. Journal of clinical psychopharmacology. (2002)
- Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Maurer, H.H., Kraemer, T., Springer, D., Staack, R.F. Therapeutic drug monitoring. (2004)
- Participation of estrogen receptors in the enhancement of osteoblast differentiation by TAK-778. Beloti, M.R., Bellesini, L.S., de Oliveira, P.T., Rosa, A.L. Mol. Cell. Biochem. (2006)
- Pitch and loudness estimation for single and multiple pulse per period electric pulse rates by cochlear implant patients. Busby, P.A., Clark, G.M. The Journal of the Acoustical Society of America. (1997)
- Application of surface modified polypropylene membranes to an anaerobic membrane bioreactor. Sainbayar, A., Kim, J.S., Jung, W.J., Lee, Y.S., Lee, C.H. Environmental technology. (2001)
- Gonadotropin independent precocious puberty. Low, L.C., Wang, Q. Journal of pediatric endocrinology & metabolism : JPEM. (1998)
- MPP6 is an exosome-associated RNA-binding protein involved in 5.8S rRNA maturation. Schilders, G., Raijmakers, R., Raats, J.M., Pruijn, G.J. Nucleic Acids Res. (2005)